Adamas Pharmaceuticals Lands $40,000,000 Series D Round

  • Feed Type
  • Date
    8/19/2009
  • Company Name
    Adamas Pharmaceuticals
  • Mailing Address
    1900 Powell Street Emeryville, CA 94608
  • Company Description
    Adamas is an emerging pharmaceutical company focused on developing small molecule, Advantaged Therapeutics™ to treat neurological and infectious diseases, including influenza A, the cause of the current flu pandemic. Adamas’ approach to pharmaceutical development is to identify and match proven drug mechanisms that can be developed as optimized combination drug therapies to increase safety, efficacy and compliance, thus improving upon the standard of care. Adamas is headquartered in Emeryville, California, with operations in Bangalore, India.
  • Website
    http://www.adamaspharma.com/
  • Transaction Type
    Venture Equity
  • Transaction Amount
    $40,000,000
  • Transaction Round
    Series D
  • Proceeds Purposes
    Proceeds purposes were not disclosed.
  • M&A Terms
  • Venture Investor
    Mohr Davidow Ventures
  • Venture Investor
    Northgate Capital
  • Venture Investor
    Aeris Capital AG
  • Venture Investor
    DAG Ventures

By posting a comment, you agree to our terms and conditions.